Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

INTRODUCTION: Endometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths. Approximately 10%–15% of women with EC are diagnosed with advanced-stage disease, resulting in a reported 5-year survival rate of only 17% for those wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Arezzo, Francesca, Giannone, Gaia, Castaldo, Daniele, Scotto, Giulia, Tuninetti, Valentina, Turinetto, Margherita, Bartoletti, Michele, Mammoliti, Serafina, Artioli, Grazia, Mangili, Giorgia, Salutari, Vanda, Lorusso, Domenica, Cormio, Gennaro, Loizzi, Vera, Zamagni, Claudio, Savarese, Antonella, Di Maio, Massimo, Ronzino, Graziana, Pisano, Carmela, Pignata, Sandro, Valabrega, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538538/
https://www.ncbi.nlm.nih.gov/pubmed/37781174
http://dx.doi.org/10.3389/fonc.2023.1247291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538538/
https://www.ncbi.nlm.nih.gov/pubmed/37781174
http://dx.doi.org/10.3389/fonc.2023.1247291

Ejemplares similares